Tirzepatide Warnings Every Patient Should Understand

Step 1, Know the warning signs that need same-day medical help

The most serious warning with tirzepatide concerns the pancreas. On 29 January 2026, the MHRA issued a Drug Safety Update confirming that acute pancreatitis is a known but infrequent risk across GLP-1 medicines. The signal to act on: severe stomach pain that does not ease, particularly if it spreads toward the back, with or without vomiting. This is not the ordinary nausea that often accompanies a new dose, it is a distinct, persistent, sharp pain. If that happens, stop eating and drinking and seek urgent medical care the same day.

Gallbladder problems are a second area to flag. Gallstones and inflammation of the gallbladder (cholecystitis) have been reported, typically presenting as pain in the upper right side of the abdomen, sometimes with fever or yellowing of the skin. An allergic reaction is rare but possible: widespread rash, swelling of the face or throat, or difficulty breathing all warrant calling 999 immediately.

A quick daily habit worth building: each morning, take ten seconds to check the injection site from the previous dose. Redness, warmth or a hard lump that spreads or persists beyond a day or two is worth reporting to your prescriber. Catching localised reactions early is straightforward when it becomes routine.

Step 2, Understand the warnings specific to medicines and hormones you already take

Tirzepatide slows how quickly the stomach empties, which affects the absorption of other oral medicines taken around the same time. This is particularly relevant for oral contraceptives. NHS England's guidance is clear: women using the pill should use an additional non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after every dose increase, because pill absorption may be reduced during those periods. There is no equivalent evidence of the same issue with semaglutide, so this is a tirzepatide-specific consideration.

For the same absorption reason, NHS England advises that women taking oral HRT should discuss switching to a transdermal option (a patch or gel) with their GP while on tirzepatide. This is a precaution rather than a prohibition, but it is one worth raising at the outset rather than after months of treatment. If you want a fuller picture of how tirzepatide affects the body day to day, including GI effects during the early weeks, that page covers the broader profile in detail.

People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) should not use tirzepatide; this is a contraindication stated in the prescribing information. The prescriber will ask about this during assessment. History of pancreatitis and certain gastrointestinal conditions also require careful review before a prescription is issued, and our dedicated Mounjaro warnings page sets out each contraindication and caution in full so you can review them before your consultation.

Step 3, Prepare for surgery and pregnancy-related decisions before they become urgent

Surgery creates a specific risk with tirzepatide. Because the medicine slows gastric emptying, stomach contents may not clear as expected before anaesthesia, raising the risk of aspiration. The guidance from NHS England is straightforward: tell every member of your surgical and anaesthetic team that you take tirzepatide well ahead of any planned procedure. For elective operations, your prescriber and surgical team may agree to pause treatment in advance; timing depends on clinical judgement. This is not a reason to avoid surgery, but an unannounced interaction could complicate an otherwise routine procedure.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. If your family plans change after starting treatment, this is a conversation to have with your prescriber promptly rather than after a positive test. Under-18s should not use tirzepatide; the licence covers adults only.

For those transferring from another provider or considering starting for the first time, the tirzepatide treatment overview sets out how eligibility is assessed and what the consultation process involves. Separately, the cancer-related warnings page covers the thyroid tumour signal from animal studies in more detail, a question that comes up often and deserves a careful, evidence-based answer.

Step 4, Report problems and know where to turn

Any suspected side effect can be reported directly to the MHRA via the Yellow Card scheme. This applies to patients as well as clinicians; you do not need a healthcare professional to submit a report on your behalf. Reporting helps the MHRA detect new signals early, which benefits everyone on the medicine.

If you are unsure whether something you are experiencing is a side effect or a warning sign that needs action, the safest approach is to contact your prescriber rather than search online. At nume, our prescribers are reachable seven days a week through our aftercare team, and clinical review is included in the cost of treatment with no extra charge for support queries. The thyroid warning page goes deeper on the MTC signal from animal data and what it means in practice for human risk. And if you have questions about how mood and mental wellbeing intersect with treatment, this page on tirzepatide and mood addresses that specifically.

Thinking about whether tirzepatide is right for you? Our prescribers are available to assess your history, medications and circumstances properly. Start your free consultation and a GPhC-registered clinician will review your answers the same day.